NEW YORK – Indivumed said today that it is partnering with Greek machine learning and analytics startup Gnosis Data Analysis to add artificial intelligence to its IndivuType multi-omics cancer research platform.
Hamburg, Germany-based Indivumed's IndivuType combines genomic, transcriptomic, proteomic, immuno-phenotype, and digital histopathology data with clinical information from thousands of cancer patients to enable research. It also features bioinformatic and AI tools for data analysis.
Gnosis Data Analysis, a spinout from the University of Crete, brings additional AI and machine learning capabilities tailored for multi-omics environments.
"The wealth of information in IndivuType can only be fully realized by using powerful analytical tools like the ones Gnosis develops," Indivumed CEO Hartmut Juhl said in a statement.
"Our Just Add Data (JAD) Bio system is specifically designed for the complexity and magnitude of multi-omics data and via our AI decision support system for model selection, we can now put unprecedented multi-omics discovery capabilities in the hands of Indivumed scientists," added Gnosis Data Analytics CEO Ioannis Tsamardinos.
This news comes a month after Indivumed partnered with fellow German company Evotec to discover and develop new precision therapeutics for colorectal cancer.